• Breakthrough Malaria Treatments Offer Hope for Elimination in High-Risk Regions

  • Mar 30 2025
  • Length: 3 mins
  • Podcast

Breakthrough Malaria Treatments Offer Hope for Elimination in High-Risk Regions

Listen for free

View show details

  • Summary

  • In recent developments, the fight against malaria has seen significant advancements, particularly in the realm of preventive measures and vaccine development.

    In northwestern Kenya, a pilot program has yielded promising results in reducing the burden of malaria. The program, which involved community health promoters administering preventive doses of antimalarial drugs to children under 5 in Turkana County, has cut cases of seasonal malaria by 70 percent among children in its first year. This initiative, part of a broader strategy known as seasonal malaria chemoprevention, is endorsed by the World Health Organization (WHO) for areas prone to seasonal malaria outbreaks. Led by researchers from Duke Global Health Institute and Moi University, the project has garnered support from various partners, including Catholic Relief Services and the Turkana County government. The success of this program has prompted Kenyan health officials to consider expanding it to other counties[1].

    On the vaccine front, there have been notable updates. Currently, two malaria vaccines are recommended for use in children living in areas with moderate to high malaria transmission. The RTS,S/AS01 vaccine, approved by the WHO in 2021, and the R21/Matrix-M vaccine, approved in 2023, have shown efficacy in reducing uncomplicated malaria by about 40%, severe malaria by 30%, and all-cause mortality by 13%[2][4].

    A recent breakthrough has come with the development of the PfSPZ-LARC2 vaccine, a genetically engineered malaria vaccine that has demonstrated 90% protection against controlled human malaria infection after a single injection. Developed by researchers from Sanaria and the Seattle Children’s Research Institute’s Center for Global Infectious Disease Research, this vaccine uses advanced genetic engineering to delete key parasite genes, ensuring the parasites replicate in the liver but do not progress to the blood stage, thus preventing malaria symptoms and transmission. This vaccine is undergoing further clinical trials in 2025 to assess its safety and efficacy across diverse populations[4].

    These advancements align with the WHO's broader goals outlined in the Malaria Vaccine Technology Roadmap, which aims to develop and license malaria vaccines with at least 75% protective efficacy against clinical malaria by 2030. The roadmap also includes developing vaccines that reduce transmission and human malaria infection, enabling elimination in multiple settings through mass vaccination campaigns[2].

    As malaria continues to be a significant public health threat, especially in regions like sub-Saharan Africa and South-East Asia, these developments offer hope for more effective prevention and control strategies. The ongoing research and implementation of these vaccines and preventive programs underscore the global commitment to combating this debilitating disease.
    Show More Show Less
Show More Show Less

What listeners say about Breakthrough Malaria Treatments Offer Hope for Elimination in High-Risk Regions

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available